Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat

Amir H. Dorafshar, Kogie Moodley, Michelle Khoe, Chris Lyon, Michael Bryer-Ash

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objective: To test the hypothesis that the thiazolidinedione agent, pioglitazone, mediates its chronic BP lowering action via improving vascular reactivity. Methods and Results: Lean (Fa/fa) and obese (fa/fa) Zucker rats were treated with or without pioglitazone (20 mg/kg/day) for 4 weeks (n=8 animals per group). Pioglitazone treatment was associated with a significant improvement in oral glucose tolerance in the obese animals (p<0.05 compared with untreated obese). Pioglitazone prevented the development of hypertension seen in obese untreated rats (SBP 126±1 versus 138±1 mmHg; p<0.0001). Aortic ring preparations from pioglitazone-treated obese rats showed improved relaxation responsiveness (ED50 0.28 versus 1.15 U/ ml, p<0.001) to SOD, a NO potentiator, compared with untreated obese animals. Conclusions: SOD-mediated vasorelaxation may contribute to the chronic antihypertensive effect and/or the improvement in insulin sensitivity following pioglitazone treatment.

Original languageEnglish (US)
Pages (from-to)20-27
Number of pages8
JournalDiabetes and Vascular Disease Research
Issue number1
StatePublished - 2010
Externally publishedYes


  • Acetylcholine
  • Aorta
  • Insulin
  • Obesity
  • Thiazolidinedione

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat'. Together they form a unique fingerprint.

Cite this